AgomAb Therapeutics NV director Patel Naimish received 56,328 derivative securities on 2026-09-11, leaving him with the same number afterward. The award represents about 100.0% of his resulting derivative-securities holding, giving investors a precise record of the director’s post-transaction position and the nature of the insider activity.
Key Highlights
- The filing records Patel Naimish’s award under transaction code A.
- The transaction occurred on 11 September 2026.
- The award represents about 100.0% of Naimish’s resulting derivative-securities holding.
AgomAb Therapeutics NV director Patel Naimish was awarded 56,328 derivative securities on 11 September 2026, and his resulting holding was listed at 56,328 derivative securities. The award represents about 100.0% of his resulting derivative-securities position. Naimish is identified as a director of AgomAb Therapeutics NV.
Award Classified as Insider Grant
The filing records the transaction under code A and states that Naimish was awarded derivative securities. The recorded security class is derivative securities of AgomAb Therapeutics NV.
FAQs
Q: What did Patel Naimish receive from AgomAb Therapeutics?
A: The filing states that Patel Naimish was awarded 56,328 derivative securities of AgomAb Therapeutics NV. It records the transaction under SEC transaction code A.
Q: How much of Patel Naimish’s resulting holding came from the transaction?
A: The transaction represents about 100.0% of Patel Naimish’s resulting derivative-securities holding. His resulting position was listed at 56,328 derivative securities.
Q: When did the AgomAb Therapeutics insider transaction occur?
A: The filing records the transaction date as 11 September 2026. It identifies Patel Naimish as a director of AgomAb Therapeutics NV and reports that he was awarded 56,328 derivative securities.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.